Chen R.,Peking Union Medical College |
Mu L.,Peking Union Medical College |
Zhang H.,Peking Union Medical College |
Xin M.,Peking Union Medical College |
And 15 more authors.
Annals of Plastic Surgery | Year: 2014
BACKGROUND: This study was designed to introduce the key points about the transplantation of lower abdominal flap with vascularized lymph node and to evaluate the effect of breast restoration, breast reconstruction, and lymphatic transplantation to treat upper limb lymphedema after breast cancer surgery. MATERIALS AND METHODS: The study was based on the retrospective study on 10 cases of postmastectomy lymphedema during January 2008 to March 2011. All patients, aged 36 to 50 years, have had one-side upper-limb lymphedema for 3 to 5 years. Six patients had accepted radiotherapy. Four patients had a diagnosis of severe lymphedema, and 2 patients had moderate lymphedema. The isotope radiography before the operation showed obstruction of lymphatic return, and the multidetector computed tomography that followed delivered a clear picture of the abdominal flap blood supply and the blood vessels in the breasts. During the operation, the scar contracture of the axilla was completely relaxed, and all patients accepted abdominal transplantation of lower abdominal flap with vascularized lymph node. After the operation, the elastic bandages were applied for one year as an adjuvant therapy. The follow-up visits were conducted 1, 3, 6, and 12 months after the surgery. The measurement indexes included mid-upper arm circumference, clinical symptoms, and lymphoscintigraphy. RESULTS: All flaps worked well. One patient was found to have delayed wound healing; one patient saw no obvious improvement in lymphedema; 7 patients with lymphedema were relieved with apparent improvement in the affected limbs' mean perimeter and clinical symptoms; one patient recovered; and another patient was lost to follow-up. The mean reduction was 2.122 ± 2.331 cm, and the reduction of the lymphedematous limb was statistically significant between the preoperative and 12-month postoperative groups (P < 0.05). The results were good in 4 patients and excellent in one patient. CONCLUSIONS: The transplantation of abdominal flap with vascularized lymph node and breast reconstruction, accompanied by the treatment to upper limb lymphedema and using elastic bandages as an adjuvant therapy, is considered to be an effective method to restore the configuration and function of breasts. Long-term follow-up visits are undergoing, especially the lymphoscintigraphy, 2 years after the operation. Copyright © 2014 by Lippincott Williams &Wilkins.
Yu M.,Fudan University |
Chen X.,Hainan Provincial Nong Ken Hospital |
Lv C.,Fudan University |
Yi X.,Shanghai Songjiang District Central Hospital |
And 5 more authors.
Biochemical and Biophysical Research Communications | Year: 2014
Osteoclasts, derived from hemopoietic progenitors of the monocyte/macrophage lineage, have a unique role in bone resorption, and are considered a potential therapeutic target in the treatment of such pathologic bone diseases as osteoporosis, rheumatoid arthritis, and periodontitis. In the present study, we demonstrate that curcumol, one of the major components of the essential oil of Rhizoma Curcumae, exhibits an inhibitory effect on receptor activator of nuclear factor kappaB ligand (RANKL)-induced osteoclast differentiation with both bone marrow-derived macrophages and RAW264.7 cells in a dose-dependent manner. In addition, RANKL-induced mRNA expression of osteoclast-specific genes, such as tartrate-resistant acid phosphatase, calcitonin receptor, and cathepsin K, is prominently reduced in the presence of curcumol. Furthermore, the molecular mechanism of action was investigated, and curcumol inhibited osteoclastogenesis by specifically impairing RANKL-induced c-Jun N-terminal kinase (JNK)/activator protein-1 (AP-1) signaling, which was further identified in rescue studies by means of anisomycin, a JNK signaling-specific activator. Taken together, these findings suggest that curcumol suppresses RANKL-induced osteoclast differentiation through the JNK/AP-1 signaling pathway, and may be useful as a therapeutic treatment for bone resorption-associated diseases. © 2014 Elsevier Inc. All rights reserved.
Lv C.,Zhongshan Hospital |
Zhang Y.,Zhongshan Hospital |
Chen X.,Zhongshan Hospital |
Chen X.,Hainan Provincial Nong Ken Hospital |
And 11 more authors.
Journal of Diabetes | Year: 2015
Background: The aim of the present study was to investigate the incidence and risk factors of new-onset diabetes after transplantation (NODAT) in liver transplant recipients and the influence of NODAT on complications and long-term patient survival. Methods: We examined 438 patients who underwent liver transplantation between April 2001 and December 2008 and were not diabetic before transplantation. Results: The mean (±SD) follow-up duration was 2.46±1.62 years. The incidence of NODAT 3, 6, 9, 12, 36, and 60 months after transplantation was 44.24%, 25.59%, 23.08%, 25.17%, 17.86%, and 18.18%, respectively. Multifactor analysis indicated that preoperative fasting plasma glucose (FPG) levels and donor liver steatosis were independent risk factors for NODAT, whereas administration of an interleukin-2 receptor (IL-2R) antagonist reduced the risk of NODAT. Compared with the no NODAT group (N-NODAT), the NODAT group had a higher rate of sepsis and chronic renal insufficiency. Mean survival was significantly longer in the N-NODAT than NODAT group. Cox regression analysis showed that pre- and/or postoperative FPG levels, tumor recurrence or metastasis, and renal insufficiency after liver transplantation were independent risk factors of mortality. Pulmonary infection or multisystem failure were specific causes of death in the NODAT group, whereas patients in both groups died primarily from tumor relapse or metastasis. Conclusions: Preoperative FPG levels and donor liver steatosis were independent risk factors for NODAT, whereas administration of an IL-2R antagonist reduced the risk of NODAT. Patients with NODAT had reduced survival and an increased incidence of sepsis and chronic renal insufficiency. Significant causes of death in the NODAT group were pulmonary infection and multisystem failure. © 2015 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd.
Wang Z.-M.,Central South University |
Wang L.,Hainan Provincial Nong Ken Hospital |
Chen X.-X.,Central South University |
Luo X.-S.,Central South University |
And 8 more authors.
Journal of Clinical Rehabilitative Tissue Engineering Research | Year: 2010
BACKGROUND: Haploidentical hematopoietic stem cell transplantation is confronted with many problems such as difficulty to implant, slow reconstitution, severe graft versus host disease, delayed immunologic reconstitution, and high incidence rate of lethal infection. To overcome these problems can widely use the transplantation of haploidentical hematopoietic stem cells. OBJECTIVE: To study the effect of haploidentical hematopoietic stem cell transplantation in treatment of hematologic malignancies. METHODS: We used cytosine arabinoside, busulphan, cyclophosphamide, the anti-thymocyte globulin and methyl-n-(2-chloroethlyl)-n-cyclohexyl-n-nitrosourea as preconditioning of patients, used cyclosporine A, mycophenolate mofetil, the anti-thymocyte globulin, interleukin-11 and methotrexate as prophylaxis of acute graft versus host diseases to treat 6 cases of hematologic malignancies. RESULTS AND CONCLUSION: All patients achieved complete engraftment. The median times of neutrophil recovery > 1.0×109/L were 15.8 (+12-+20) days after transplantation. The incidence of grade III-IV graft-versus-host disease was 16.7%. All patients survived disease-free with a median follow-up of 34.7(13-63) months. Results have indicated that haploidentical hematopoietic stem cell transplantation is a safe and effective treatment for hematologic malignancies, with cytosine arabinoside, busulphan, cyclophosphamide, the anti-thymocyte globulin, methyl-n-(2-chloroethlyl)-n-cyclohexyl-n-nitrosourea as preconditioning, with cyclosporine A, mycophenolate mofetil, the anti-thymocyte globulin, interleukin-11 and methotrexate as prophylaxis of acute graft versus host diseases.
He E.-X.,Hainan Provincial Nong Ken Hospital |
Nie Z.-S.,Hainan Provincial Nong Ken Hospital |
Zhang Y.-H.,Hainan Provincial Nong Ken Hospital |
Lin H.-F.,Hainan Provincial Nong Ken Hospital
Chinese Journal of Tissue Engineering Research | Year: 2013
Background: Liver cancer is one of the common malignant tumor, and choosing the effective therapy and treatment method has great significance for the treatment of liver cancer. Objective: To evaluate the targeting therapy effect of the carrier sustained-release chemotherapy drugs for the treatment of liver cancer. Methods: The clinical commonly used liver cancer chemotherapy drugs included the 5-fluorouracil, mitomycin and epirubicin vector sustained-release system, and the tumor targeting characteristics and suppression and killing effect of these cancer chemotherapy drugs on the tumor were analyzed. A total of 163 patients with advanced liver cancer were selected from Department of Medical Oncology, Hainan Provincial Nong Ken Hospital. The patients were treated with 5-fluorouracil, mitomycin and epirubicin combined with the adjuvant treatment of transcatheter arterial chemoembolization, and then the clinical effect was observed.Results and Conclusion: 5-fluorouracil, mitomycin and epirubicin vector sustained release system show the targeting characteristics to liver tumor through different mechanisms, and have strong inhibiting and killing effect on liver tumors. And the cancer chemotherapy drugs can reduce the drug consumption, decrease the toxicity side effect and thus improve the therapeutic effect. In addition, the combination of transcatheter arterial chemoembolization can prolong the survival of the patients and improve the therapeutic effect of liver cancer.